Cargando…
CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders
Astrocytic impairment is a pathologic feature of neuromyelitis optica spectrum disorder (NMOSD). S100B and glial fibrillary acidic protein (GFAP) are the two most commonly used astrocytic markers. The aim of this study was to evaluate whether CSF-S100B could serve as a marker of NMOSD. We enrolled 4...
Autores principales: | Wei, Yuzhen, Chang, Haoxiao, Li, Xindi, Du, Li, Xu, Wangshu, Cong, Hengri, Yao, Yajun, Zhang, Xinghu, Yin, Linlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217894/ https://www.ncbi.nlm.nih.gov/pubmed/30426010 http://dx.doi.org/10.1155/2018/5381239 |
Ejemplares similares
-
Profile and potential role of novel metabolite biomarkers, especially indoleacrylic acid, in pathogenesis of neuromyelitis optica spectrum disorders
por: Bian, Jiangping, et al.
Publicado: (2023) -
Targeting chemoattractant chemokine (C–C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders
por: Wang, Yupeng, et al.
Publicado: (2023) -
Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder
por: Chang, Haoxiao, et al.
Publicado: (2021) -
Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: A retrospective observational study
por: Du, Li, et al.
Publicado: (2020) -
Cortical Thinning and Ventricle Enlargement in Neuromyelitis Optica Spectrum Disorders
por: Tian, De-Cai, et al.
Publicado: (2020)